|Bid||12.65 x 2900|
|Ask||13.50 x 1000|
|Day's Range||12.44 - 15.50|
|52 Week Range||10.33 - 24.56|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
ROCKVILLE, Md. and HONG KONG , Jan. 8, 2019 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other ...
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug (IND) application and executed the compound license agreement for the compound with Ascentage Pharma Group Corp Limited (“Ascentage Pharma”) under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema.
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
SAN FRANCISCO, Dec. 04, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will include an additional cohort of patients in the Phase 1 single ascending dose clinical study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. UNITY has completed enrollment in Cohorts 1 through 5 (0.1 to 2 mg dose). The amendment follows an interim review of aggregate blinded safety and tolerability, and drug exposure data from these cohorts.
SAN FRANCISCO, Oct. 31, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
If you want to know who really controls Unity Biotechnology Inc (NASDAQ:UBX), then you’ll have to look at the makeup of its share registry. Institutions often own shares in moreRead More...
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC’s “Power Lunch” about the company’s plans. Amazon CEO Jeff Bezos is an investor in the company.
"The evidence is mounting, both in our company and outside, that you can intervene and you can change the course of these specific diseases," says Unity Biotechnology CEO Keith Leonard.
Unity Biotechnology is a company designing drugs and treatments that can make a person functional and free of the diseases associated with aging for as long as possible. The company — backed by Jeff Bezos and Peter Thiel —went public in May and is listed on NASDAQ. Of the many people currently involved in searching for ways to slow down or delay the effects of growing older, Nathaniel David might actually have a shot.
LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On June 11, 2018, the Company announced that it has signed a partnership deal with Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. Active-Investors.com is currently working on the research report for Unity Biotechnology, Inc. (NASDAQ: UBX), which also belongs to the Healthcare sector as the Company Alexion Pharma.